Dr. Bogdana Schmidt

Are you seeing this as a positive, meaning you would extend this, basically this treatment paradigm to those patients up front, or do you want more data for that specific patient population?

Practical question again, just because I have the expert here. What about plasma cytoid, high volume plasma cytoid? Are you scanning those patients differently? Are you surveilling them any differently or about the same? Those are the patients that I always worry about. What if they're progressing on treatment? What if I'm missing a resectability window?

Practical question again, just because I have the expert here. What about plasma cytoid, high volume plasma cytoid? Are you scanning those patients differently? Are you surveilling them any differently or about the same? Those are the patients that I always worry about. What if they're progressing on treatment? What if I'm missing a resectability window?

Practical question again, just because I have the expert here. What about plasma cytoid, high volume plasma cytoid? Are you scanning those patients differently? Are you surveilling them any differently or about the same? Those are the patients that I always worry about. What if they're progressing on treatment? What if I'm missing a resectability window?

Excellent. Well, thank you. Again, I think this is really interesting and promising data and certainly already has the potential to be practice changing as it is. And we'll just continue to learn more and more from it. Some of the questions that we'll be looking to learn from it will actually hit on discussing a few of the other studies.

Excellent. Well, thank you. Again, I think this is really interesting and promising data and certainly already has the potential to be practice changing as it is. And we'll just continue to learn more and more from it. Some of the questions that we'll be looking to learn from it will actually hit on discussing a few of the other studies.

Excellent. Well, thank you. Again, I think this is really interesting and promising data and certainly already has the potential to be practice changing as it is. And we'll just continue to learn more and more from it. Some of the questions that we'll be looking to learn from it will actually hit on discussing a few of the other studies.

So maybe we can move on to talking about your trial, talking about Ambassador.

So maybe we can move on to talking about your trial, talking about Ambassador.

So maybe we can move on to talking about your trial, talking about Ambassador.

Absolutely. And like you said earlier, you know, we already had nivolumab approved before. So that's two positive trials in this space. We didn't really talk about Invigor, the earlier Atizo trial that didn't meet its primary endpoint, which could be related to the Atizo, could be related to where the trials were structured.

Absolutely. And like you said earlier, you know, we already had nivolumab approved before. So that's two positive trials in this space. We didn't really talk about Invigor, the earlier Atizo trial that didn't meet its primary endpoint, which could be related to the Atizo, could be related to where the trials were structured.

Absolutely. And like you said earlier, you know, we already had nivolumab approved before. So that's two positive trials in this space. We didn't really talk about Invigor, the earlier Atizo trial that didn't meet its primary endpoint, which could be related to the Atizo, could be related to where the trials were structured.

But certainly, I think we have enough data now that adjuvant therapy in the post-cystectomy setting with nivolumab or pembrolizumab is here, right? So based on this, and obviously I know you have a little bias potentially because it's your data and you're familiar with it. So it's a good bias. If and when both drugs are approved and available in the clinic space, how will you choose between them?

But certainly, I think we have enough data now that adjuvant therapy in the post-cystectomy setting with nivolumab or pembrolizumab is here, right? So based on this, and obviously I know you have a little bias potentially because it's your data and you're familiar with it. So it's a good bias. If and when both drugs are approved and available in the clinic space, how will you choose between them?

But certainly, I think we have enough data now that adjuvant therapy in the post-cystectomy setting with nivolumab or pembrolizumab is here, right? So based on this, and obviously I know you have a little bias potentially because it's your data and you're familiar with it. So it's a good bias. If and when both drugs are approved and available in the clinic space, how will you choose between them?

Yeah.

Yeah.

Yeah.

Is there any patient population or anything, just knowing, obviously, cross-trial comparisons are so fraught with so many problems, but is there any patient population for whom you might say, maybe nivolumab, we have slightly better data for? Or do you feel like the dosing schedule of Pembro kind of trumps things?